TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects
Brief Summary: The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine lipoarabinomannan (LAM) test in detecting tuberculosis in HIV-infected adults.

A secondary study objective is to determine the accuracy, efficiency, costs, and cost-effectiveness of various combinations of Tuberculosis (TB) diagnostic tests, including the novel Xpert MTB/Rif test.


Options:
A: Arm Label: Xpert MTB/Rif; Type: EXPERIMENTAL; Interventions: Other: Xpert MTB/Rif | Arm Label: Sputum smear; Type: ACTIVE_COMPARATOR; Interventions: Other: Smear microscopy | Intervention Type: OTHER; Name: Xpert MTB/Rif; Assigned to Arm(s): Xpert MTB/Rif | Intervention Type: OTHER; Name: Smear microscopy; Assigned to Arm(s): Sputum smear
B: Arm Label: Case detection group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Arm Label: Drug resistance risk group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Intervention Type: DEVICE; Name: Investigational Xpert DST test; Assigned to Arm(s): Case detection group, Drug resistance risk group
C: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A
D: Arm Label: Xpert MTB/RIF; Type: EXPERIMENTAL; Interventions: Procedure: Xpert MTB/RIF assay | Arm Label: Sputum smear microscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: Xpert MTB/RIF assay; Assigned to Arm(s): Xpert MTB/RIF | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Sputum smear microscopy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke: a Randomised, Double-blind, Placebo-controlled Trial
Brief Summary: WAKE-UP is an investigator initiated European multicenter randomized controlled clinical trial of MRI based thrombolysis in acute stroke patients with unknown time of symptom onset, e.g. due to recognition of stroke symptoms on awakening. Objective of WAKE-UP is to prove efficacy and safety of MRI-based intravenous thrombolysis with Alteplase in patients waking up with stroke symptoms or patients with otherwise unknown symptom onset.


Options:
A: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Alteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alteplase; Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Sham Stimulation; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial Direct Current Stimulation | Arm Label: Active Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial Direct Current Stimulation | Intervention Type: DEVICE; Name: Transcranial Direct Current Stimulation; Assigned to Arm(s): Active Stimulation, Sham Stimulation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke: a Randomised, Double-blind, Placebo-controlled Trial
Brief Summary: WAKE-UP is an investigator initiated European multicenter randomized controlled clinical trial of MRI based thrombolysis in acute stroke patients with unknown time of symptom onset, e.g. due to recognition of stroke symptoms on awakening. Objective of WAKE-UP is to prove efficacy and safety of MRI-based intravenous thrombolysis with Alteplase in patients waking up with stroke symptoms or patients with otherwise unknown symptom onset.


Options:
A: Arm Label: Group with endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rescue endovascular therapy | Arm Label: Group without endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No endovascular therapy | Intervention Type: PROCEDURE; Name: Rescue endovascular therapy; Assigned to Arm(s): Group with endovascular treatment | Intervention Type: PROCEDURE; Name: No endovascular therapy; Assigned to Arm(s): Group without endovascular treatment
B: Arm Label: Best medical management.; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Additional intra-arterial treatment.; Type: EXPERIMENTAL; Interventions: Other: Intra-arterial treatment | Intervention Type: OTHER; Name: Intra-arterial treatment; Assigned to Arm(s): Additional intra-arterial treatment.
C: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Alteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alteplase; Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lactoferrin for Prevention of Sepsis in Infants
Brief Summary: The investigators propose a clinical trial in premature infants to determine the effect of orally-administered bovine lactoferrin on occurrence of severe infections and to determine whether as a result of decreased infections, infants' growth and development improve after daily lactoferrin supplementation, due to its antimicrobial and anti-inflammatory properties. If successful, the use of lactoferrin as a protective protein could profoundly affect clinical care of neonates both in the developed and developing world.


Options:
A: Arm Label: Lactoferrin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: lactoferrin | Arm Label: maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: lactoferrin; Assigned to Arm(s): Lactoferrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): maltodextrin
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: bovine lactoferrin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo [maltodextrin] | Intervention Type: DIETARY_SUPPLEMENT; Name: bovine lactoferrin; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo [maltodextrin]; Assigned to Arm(s): B
C: Arm Label: Bovine Lactoferrin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Bovine Lactoferrin | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bovine Lactoferrin; Assigned to Arm(s): Bovine Lactoferrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Talactoferrin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Talactoferrin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy
Brief Summary: The purpose of this study is to demonstrate that Acceptance Therapy (ACT's) implementation outcomes are at least as good as those of traditional cognitive behavioral therapy (CBT).

Implementation outcomes:

* end of treatment and 6-month follow-up data retention rates;
* intervention implementation quality;
* number \& length of calls completed.

Comparison of each arm's implementation


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: yoga, Behavioral: cognitive therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive therapy, Behavioral: wellness | Intervention Type: BEHAVIORAL; Name: yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: cognitive therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: wellness; Assigned to Arm(s): 2
B: Arm Label: Mindfulness Training for Smokers; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Training for Smokers | Arm Label: Integrated Training for Smokers; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Integrated Training for Smokers | Arm Label: Quitline; Type: OTHER; Interventions: Behavioral: Quitline | Intervention Type: BEHAVIORAL; Name: Integrated Training for Smokers; Assigned to Arm(s): Integrated Training for Smokers | Intervention Type: BEHAVIORAL; Name: Mindfulness Training for Smokers; Assigned to Arm(s): Mindfulness Training for Smokers | Intervention Type: BEHAVIORAL; Name: Quitline; Assigned to Arm(s): Quitline
C: Arm Label: ACT; Type: EXPERIMENTAL; Interventions: Behavioral: Acceptance Therapy (ACT) | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Other: Cognitive Behavioral Therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Acceptance Therapy (ACT); Assigned to Arm(s): ACT | Intervention Type: OTHER; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT
D: Arm Label: Mindfulness Based Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness based smoking cessation | Arm Label: Behavioral Smoking Cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Smoking Cessation intervention | Intervention Type: BEHAVIORAL; Name: Mindfulness based smoking cessation; Assigned to Arm(s): Mindfulness Based Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Smoking Cessation intervention; Assigned to Arm(s): Behavioral Smoking Cessation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cervical Cancer Screening and Adherence to Follow-up Among Hispanic Women
Brief Summary: In this study, 400 Hispanic women will be recruited and randomized to one of three interventions:

1. Control (no change);
2. A low-intensity information program, consisting of a video approach educating women on the importance of cervical cancer screening;
3. A higher intensity program consisting of the video plus a 'promotora' or lay-community health educator led intervention at the participant's home to encourage cervical cancer screening.

The investigators will compare which intervention is most effective in encouraging Hispanic women to undergo cervical cancer screening (Pap test)


Options:
A: Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Arm Label: Lay Health Advisor Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lay Health Advisor Education Intervention | Intervention Type: BEHAVIORAL; Name: Lay Health Advisor Education Intervention; Assigned to Arm(s): Lay Health Advisor Intervention | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity Information (DVD); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DVD | Arm Label: High Intensity Information (Promotora); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Promotora | Intervention Type: BEHAVIORAL; Name: DVD; Assigned to Arm(s): Low Intensity Information (DVD) | Intervention Type: BEHAVIORAL; Name: Promotora; Assigned to Arm(s): High Intensity Information (Promotora)
C: Arm Label: Stepwise intervention; Type: EXPERIMENTAL; Interventions: Other: Customized text message invitation ( Step 1a), Other: Customized automatic phone call invitation (Step 1b), Other: Secretary phone call (Step 2), Other: Health professional face-to-face appointment (Step 3) | Arm Label: Written Letter; Type: ACTIVE_COMPARATOR; Interventions: Other: Written Letter | Intervention Type: OTHER; Name: Customized text message invitation ( Step 1a); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Customized automatic phone call invitation (Step 1b); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Secretary phone call (Step 2); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Health professional face-to-face appointment (Step 3); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Written Letter; Assigned to Arm(s): Written Letter
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Preventive Health Record (IPHR) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: "Standard" preventive care | Intervention Type: BEHAVIORAL; Name: Interactive Preventive Health Record (IPHR); Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: "Standard" preventive care; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Efficacy Research of Uni- vs Bi-lateral Arm Training Poststroke: Task-Related or Robotic
Brief Summary: This proposed project aims to

* compare the effects of dose-matched unilateral vs bilateral vs unilateral combined with bilateral upper limb rehabilitation based on task-related practice
* compare the effects of unilateral vs bilateral training based on robot-assisted devices
* study the predictors of treatment outcomes and clinimetric properties of the biomechanical measures


Options:
A: Intervention Type: DEVICE; Name: robotic device; Assigned to Arm(s): N/A
B: Arm Label: Task-Related UAT; Type: EXPERIMENTAL; Interventions: Behavioral: Task-related unilateral arm training | Arm Label: Task-Related BAT; Type: EXPERIMENTAL; Interventions: Behavioral: Task-related bilateral arm training | Arm Label: Task-Related UAT coupling BAT; Type: EXPERIMENTAL; Interventions: Behavioral: Task-related unilateral arm training, Behavioral: Task-related bilateral arm training | Arm Label: Robot-assisted UAT; Type: EXPERIMENTAL; Interventions: Behavioral: Robot-assisted unilateral arm training | Arm Label: Robot-assisted BAT; Type: EXPERIMENTAL; Interventions: Behavioral: Robot-assisted bilateral arm training | Intervention Type: BEHAVIORAL; Name: Task-related unilateral arm training; Assigned to Arm(s): Task-Related UAT, Task-Related UAT coupling BAT | Intervention Type: BEHAVIORAL; Name: Task-related bilateral arm training; Assigned to Arm(s): Task-Related BAT, Task-Related UAT coupling BAT | Intervention Type: BEHAVIORAL; Name: Robot-assisted bilateral arm training; Assigned to Arm(s): Robot-assisted BAT | Intervention Type: BEHAVIORAL; Name: Robot-assisted unilateral arm training; Assigned to Arm(s): Robot-assisted UAT
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Device: Robotic Upper Extremity Neurorehabilitation | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional Upper Extremity Exercise Group | Intervention Type: DEVICE; Name: Robotic Upper Extremity Neurorehabilitation; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Traditional Upper Extremity Exercise Group; Assigned to Arm(s): Arm 2
D: Arm Label: Experimental Group (EG); Type: EXPERIMENTAL; Interventions: Device: Robot therapy (NeReBot), Other: Conventional therapy | Arm Label: Control Group (CG); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional therapy | Intervention Type: DEVICE; Name: Robot therapy (NeReBot); Assigned to Arm(s): Experimental Group (EG) | Intervention Type: OTHER; Name: Conventional therapy; Assigned to Arm(s): Control Group (CG), Experimental Group (EG)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Study of Topical Rapamycin to Erase Angiofibromas in TSC-Multicenter Evaluation of a Novel Therapy
Brief Summary: The study is a multi-center prospective, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of a topically applied formulation of rapamycin to cutaneous angiofibromas in subjects with Tuberous Sclerosis Complex (TSC). Subjects will apply either the topical vehicle containing rapamycin or the topical vehicle alone nightly to their angiofibromas for six months.

The primary goal of this study is to evaluate the efficacy of the topical medication for reduction of cutaneous angiofibromas in patients with TSC. The secondary goal of this study is to confirm the safety of the topical medication.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 0.1 % Rapamycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rapamycin | Arm Label: 1% Rapamycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): 0.1 % Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): 1% Rapamycin
B: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
C: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A
D: Arm Label: TSC Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: TSC 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: TSC 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Arm Label: NF1 Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: NF1 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: NF1 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Intervention Type: DRUG; Name: Skincerity; Assigned to Arm(s): NF1 Placebo Arm, TSC Placebo Arm | Intervention Type: DRUG; Name: Skincerity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 1% Arm, TSC 1% Arm | Intervention Type: DRUG; Name: Skinercity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 5% Arm, TSC 5% Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Craniosacral Therapy on Chronic Neck Pain: A Randomized Controlled Trial
Brief Summary: The purpose of this randomized controlled trial is to determinate the efficacy and safety of Craniosacral Therapy in the treatment of chronic unspecific neck pain.


Options:
A: Arm Label: Manual Therapy + Analgesic therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual Therapy, Device: Analgesic therapy | Arm Label: Myofascial Release + Analgesic therapy; Type: EXPERIMENTAL; Interventions: Other: Myofascial Release Therapy, Device: Analgesic therapy | Intervention Type: OTHER; Name: Manual Therapy; Assigned to Arm(s): Manual Therapy + Analgesic therapy | Intervention Type: OTHER; Name: Myofascial Release Therapy; Assigned to Arm(s): Myofascial Release + Analgesic therapy | Intervention Type: DEVICE; Name: Analgesic therapy; Assigned to Arm(s): Manual Therapy + Analgesic therapy, Myofascial Release + Analgesic therapy
B: Arm Label: Dry Needling of trigger point; Type: EXPERIMENTAL; Interventions: Other: Dry needling | Arm Label: Strain-counterstraing technique; Type: EXPERIMENTAL; Interventions: Other: Strain-counterstrain technique | Arm Label: Placebo manual technique; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo manual technique | Intervention Type: OTHER; Name: Dry needling; Assigned to Arm(s): Dry Needling of trigger point | Intervention Type: OTHER; Name: Strain-counterstrain technique; Assigned to Arm(s): Strain-counterstraing technique | Intervention Type: OTHER; Name: Placebo manual technique; Assigned to Arm(s): Placebo manual technique
C: Arm Label: Craniosacral Therapy (CST); Type: EXPERIMENTAL; Interventions: Procedure: Craniosacral Therapy | Arm Label: Sham Craniosacral Therapy (SHAM); Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Craniosacral Therapy | Intervention Type: PROCEDURE; Name: Craniosacral Therapy; Assigned to Arm(s): Craniosacral Therapy (CST) | Intervention Type: PROCEDURE; Name: Sham Craniosacral Therapy; Assigned to Arm(s): Sham Craniosacral Therapy (SHAM)
D: Arm Label: EXPERIMENTAL GROUP; Type: EXPERIMENTAL; Interventions: Procedure: Physiotherapy treatment | Arm Label: CONTROL GROUP; Type: EXPERIMENTAL; Interventions: Procedure: Physiotherapy treatment | Intervention Type: PROCEDURE; Name: Physiotherapy treatment; Assigned to Arm(s): EXPERIMENTAL GROUP | Intervention Type: PROCEDURE; Name: Physiotherapy treatment; Assigned to Arm(s): CONTROL GROUP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study
Brief Summary: The investigators examined whether a combined therapy with low-dose spironolactone plus metformin is more effective than metformin alone in 52 overweight/obese Polycystic Ovary Syndrome (PCOS) patients.


Options:
A: Arm Label: 3 mg drospirenone and 20 µg ethinyl-estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 mg drospirenone and 20 µg ethinyl-estradiol | Arm Label: 3 mg drospirenone and 30 µg ethinyl-estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 mg drospirenone and 30 µg ethinyl-estradiol | Intervention Type: DRUG; Name: 3 mg drospirenone and 20 µg ethinyl-estradiol; Assigned to Arm(s): 3 mg drospirenone and 20 µg ethinyl-estradiol | Intervention Type: DRUG; Name: 3 mg drospirenone and 30 µg ethinyl-estradiol; Assigned to Arm(s): 3 mg drospirenone and 30 µg ethinyl-estradiol
B: Intervention Type: DRUG; Name: metformin XR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin and Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Metformin plus spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin plus Spironolactone | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Metformin plus Spironolactone; Assigned to Arm(s): Metformin plus spironolactone

Answer: D